Recent Advances, Future Directions and Clinical Outcomes of Hepatectomy in Hepatocellular Carcinoma

Abstract

Background: Hepatocellular carcinoma (HCC) represents the predominant and most fatal malignancy globally. The primary therapeutic approach for HCC is Hepatectomy, which presents a potential for curative outcomes. This analysis aims to offer an exhaustive examination of the clinical repercussions linked to liver resection or Hepatectomy in HCC, underscore recent advancements in surgical methodologies, and deliberate on future pathways to enhance treatment efficacy in this domain. Methods: A thorough exploration of the literature was carried out across prominent databases, including Google Scholar, PubMed, ScienceDirect, and Cochrane Library. Research articles were chosen based on their pertinence to the outcomes of Hepatectomy in HCC, advancements in surgical techniques, and forthcoming therapeutic schemes to scrutinize the short- and long-term clinical consequences and the variables influencing these outcomes. Results: Hepatectomy for HCC manifests notable diversity in clinical outcomes, impacted by the nature of the tumor, characteristics of the patient cohort, and proficiency of the surgical team. Short-term results, like perioperative morbidity and mortality rates, have demonstrated enhancements in tandem with refinements in preoperative evaluations and intraoperative management. The duration of outcomes, encompassing overall survival and disease-free survival, displayed significant associations with extended resections, tumor characteristics, and postoperative assessments. Recent progressions in Hepatectomy have played a role in diminishing perioperative complications and expediting the recovery process. Furthermore, the amalgamation of adjuvant and neoadjuvant therapies, alongside the emergence of pharmaceutical modalities, can elevate survival rates and enhance the quality of life for individuals with HCC. Conclusion: Hepatectomy emerges as a pivotal intervention for HCC, yielding progressively superior outcomes owing to technological advancements and enhanced perioperative care. Prospective investigations will refine surgical techniques, optimize adjuvant therapies, and formulate robust predictive frameworks for diverse therapeutic modalities. This comprehensive assessment accentuates the significance of sustained innovation and interdisciplinary cooperation to elevate the standard of care for HCC patients. Moreover, continuous investigation into adjuvant and neoadjuvant treatments, such as immunotherapy and targeted therapies, is imperative for enhancing long-term prognoses.